Back to search

Article

Safety Surveillance During the Introduction of Novel Oral Poliovirus Vaccine Type 2 (nOPV2) in the Central African Republic: Findings from Passive AEFI and Active AESI Surveillance

2026-07-25

Abstract excerpt

<title>Abstract</title> <p>Background Passive surveillance of adverse events following immunization (AEFI) and active surveillance of adverse events of special interest (AESI) were implemented during the introduction of novel oral poliovirus vaccine type 2 (nOPV2) in the Central African Republic (CAR). This study aimed to describe the epidemiological and clinical characteristics of AEFIs reported during the intr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6e07820b-67d5-58af-a878-431290b831b5
DOI
10.21203/rs.3.rs-10144680/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety Surveillance During the Introduction of Novel Oral Poliovirus Vaccine Type 2 (nOPV2) in the Central African Republic: Findings from Passive AEFI and Active AESI SurveillanceDOI 10.21203/rs.3.rs-10144680/v1
Monitoring the Risk of Type-2 Circulating Vaccine-Derived Poliovirus Emergence during Roll-Out of Type-2 Novel Oral Polio VaccineSemantic proximity
First-in-human, phase 1, randomized, observer-blind, controlled trial to assess the safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adultsSemantic proximity
Different Emergence Groups of Circulating Vaccine-Derived Poliovirus Type 2 (cVDPV2-n) Outbreak Linked to Novel Oral Polio Vaccine Type 2 in a Chronic Humanitarian Contexts. A Retrospective Descriptive Analysis, South Sudan, 2023–2024Semantic proximity
An objective systematic comparison of the most common adverse events of COVID-19 vaccinesSemantic proximity
Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent VaccinesSemantic proximity
Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV StudySemantic proximity
The Post-Acute Covid-Vaccination Syndrome in the light of PharmacovigilanceSemantic proximity
Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017Semantic proximity
Current epidemiological situation of COVID-19 in the Republic of Belarus: characteristics of the epidemic process, sanitary and anti-epidemic measuresSemantic proximity
Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025Semantic proximity
Programmatic considerations for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: stakeholder analysisSemantic proximity
Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from GreeceSemantic proximity
Select a neighboring publication to make it the new centre.